首页> 外国专利> Fermentation medium, useful e.g. to cultivate strain of Corynebacterium diphtheriae to prepare diphtheria toxin, comprises water, nitrogen source, carbon source and iron additive, where medium is free of ingredients from animal origin

Fermentation medium, useful e.g. to cultivate strain of Corynebacterium diphtheriae to prepare diphtheria toxin, comprises water, nitrogen source, carbon source and iron additive, where medium is free of ingredients from animal origin

机译:发酵培养基,有用的,例如培养白喉棒状杆菌菌株以制备白喉毒素,包括水,氮源,碳源和铁添加剂,其中的培养基不含动物来源的成分

摘要

Fermentation medium comprises water, a nitrogen source, a carbon source and an iron additive, where a culture of Corynebacterium diphtheriaein at least 100 l of the fermentation medium yields at least 140 Lf/ml of diphtheria toxin or its derivative and the medium is free of ingredients from animal origin. Independent claims are included for: (1) preparing the fermentation medium comprising adding the nitrogen source, carbon source and iron additive into water; (2) preparing diphtheria toxin or its derivative to prepare a vaccine for humans comprising (a) preparing a culture of strain of Corynebacterium diphtheriae, which prepares the diphtheria toxin or its derivative, in at least 100 l of the fermentation medium containing the nitrogen source, at least 0.08 M of the carbon source, 1.5-30 mu M of soluble iron 2 +/iron 3 +, phosphorus and growth factors, (b) culturing the strain under aerobic conditions to form a concentration of at least 140 Lf/ml of the diphtheria toxin or its derivative and (c) separating the diphtheria toxin from the fermentation medium, where the separation step comprises a centrifugation step and a filtration step; (3) preparing a combination vaccine comprising carrying out the steps (a)-(c) as above per se, (d) adding formaldehyde to the diphtheria toxin or its derivative to obtain diphtheria toxoid and (e) mixing the diphtheria toxoid with at least one supplementary, protective antigen of a pathogen, which is not Corynebacterium diphtheriae; (4) preparing a diphtheria toxoid comprising either (a1) culturing the strain of Corynebacterium diphtheriae, expressing diphtheria toxin or its derivative, in at least 100 l of the fermentation medium, (b1) separating the diphtheria toxin or its derivative from the fermentation medium to obtain a diphtheria toxin solution, (c1) preparing a diphtheria toxin concentrate from the diphtheria toxin solution, where the concentration of the diphtheria toxin or its derivative in the concentrate is at least 20 times higher than the concentration of the diphtheria toxin or its derivative in the fermentation medium at the end of the step (a1) and (d1) detoxifying the diphtheria toxin concentrate, or (a2) culturing the strain of Corynebacterium diphtheriaein at least 100 l of the fermentation medium, which is free of ingredients from animal origin and optionally contains yeast extract, (b2) purifying the diphtheria toxin or its derivative from the fermentation medium to obtain purified diphtheria toxin or its derivative, where the purified diphtheria toxin has a purity of at least 85% and a purity of = 1500 Lf/mg of nitrogen, (c2) adding the formaldehyde to the purified diphtheria toxin or its derivative and (d2) incubating the purified diphtheria toxin or its derivative, or (a3) preparing a solution of the diphtheria toxin or its derivative in a concentration of at least 2000 Lf/ml, (b3) adding a solution containing an amide in a final concentration of = 0.025 M and formaldehyde in a final concentration of 0.75-1% and (c3) incubating the solution; (5) the diphtheria toxoid obtained by the above method, where the diphtheria toxoid is crosslinked by formaldehyde with at least one ingredient of the fermentation medium; (6) a composition (TT) comprising the diphtheria toxoid with a power of at least 60 international unit/ml; (7) a composition comprising a formaldehyde-crosslinked diphtheria toxoid with an isoelectric point of 4-5, where at least 70% of the toxoid is in monomer form; (8) a composition comprising the formaldehyde-crosslinked diphtheria toxoid and the protective antigen of a pathogen, which is not Corynebacterium diphtheriae; (9) a composition (AA) comprising 100-250 Lf/ml of the diphtheria toxoid and 40-100 Lf/ml of tetanus toxoid, where the ratio of the diphtheria toxoid to tetanus toxoid is 2:1-3:1; (10) preparing a human vaccine comprising mixing the composition (AA) with at least one further antigen-containing composition; and (11) a composition (BB) comprising the diphtheria toxoid, where (BB) is adsorbed in insoluble aluminum salt adjuvant (e.g. aluminum hydroxide). ACTIVITY : Antibacterial. MECHANISM OF ACTION : Vaccine.
机译:发酵培养基包括水,氮源,碳源和铁添加剂,其中白喉棒杆菌培养物至少100升发酵培养基产生至少140 Lf / ml白喉毒素或其衍生物,且该培养基不含来自动物的成分。包括以下独立权利要求:(1)制备发酵培养基,包括将氮源,碳源和铁添加剂添加到水中; (2)制备白喉毒素或其衍生物以制备用于人的疫苗,其包括(a)在至少100μl含有氮源的发酵培养基中制备白喉棒状杆菌菌株的培养物,该菌株制备白喉毒素或其衍生物。 ,至少0.08 M的碳源,1.5-30μM的可溶性铁2> +> /铁3> +>,磷和生长因子,(b)在有氧条件下培养菌株,使其浓度至少达到140Lf / ml的白喉毒素或其衍生物,和(c)从发酵培养基中分离白喉毒素,其中分离步骤包括离心步骤和过滤步骤; (3)制备组合疫苗,包括本身进行上述步骤(a)-(c),(d)在白喉毒素或其衍生物中添加甲醛以获得白喉类毒素,和(e)将白喉类毒素与病原体的至少一种补充保护性抗原,不是白喉棒状杆菌; (4)制备白喉类毒素,包括(a1)在至少100μl发酵培养基中培养表达白喉毒素或其衍生物的白喉棒状杆菌菌株,(b1)从发酵培养基中分离白喉毒素或其衍生物。为了获得白喉毒素溶液,(c1)从白喉毒素溶液制备白喉毒素浓缩物,其中浓缩物中白喉毒素或其衍生物的浓度比白喉毒素或其衍生物的浓度高至少20倍。在步骤(a1)和(d1)结束后,将白喉毒素浓缩液解毒,或(a2)培养至少100升不含动物来源成分的白喉棒状杆菌菌株(b2)从发酵培养基中纯化白喉毒素或其衍生物,以获得纯化的白喉;毒素或其衍生物,其中纯化的白喉毒素的纯度至少为85%,氮的纯度为1500 Lf / mg,(c2)将甲醛添加到纯化的白喉毒素或其衍生物中,并(d2)孵育纯化的白喉毒素或其衍生物,或(a3)制备浓度至少为2000 Lf / ml的白喉毒素或其衍生物的溶液,(b3)加入最终浓度为0.025 M的含酰胺溶液,以及最终浓度为0.75-1%的甲醛,并(c3)孵育溶液; (5)通过上述方法获得的白喉类毒素,其中白喉类毒素通过甲醛与发酵培养基的至少一种成分交联。 (6)组合物(TT),其包含白喉类毒素,其功效为至少60国际单位/ ml; (7)组合物,其包含等电点为4-5的甲醛交联的白喉类毒素,其中至少70%的类毒素为单体形式; (8)一种组合物,其包含甲醛交联的白喉类毒素和不是白喉棒状杆菌的病原体的保护性抗原。 (9)组合物(AA),其包含100-250 Lf / ml的白喉类毒素和40-100 Lf / ml的破伤风类毒素,其中白喉类毒素与破伤风类毒素的比例为2:1-3:1; (10)制备人疫苗,包括将组合物(AA)与至少一种其他的含抗原的组合物混合; (11)包含白喉类毒素的组合物(BB),其中(BB)被吸附在不溶的铝盐佐剂(例如氢氧化铝)中。活动:抗菌。作用机理:疫苗。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号